These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15616642)

  • 1. Case histories in drug discovery and design.
    SMR Committee
    Drug News Perspect; 1998 Feb; 11(1):52-7. PubMed ID: 15616642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
    Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH
    Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
    Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
    J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.
    Gobbi S; Cavalli A; Rampa A; Belluti F; Piazzi L; Paluszcak A; Hartmann RW; Recanatini M; Bisi A
    J Med Chem; 2006 Jul; 49(15):4777-80. PubMed ID: 16854084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
    Dayam R; Sanchez T; Neamati N
    ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability.
    Tangallapally RP; Lee RE; Lenaerts AJ; Lee RE
    Bioorg Med Chem Lett; 2006 May; 16(10):2584-9. PubMed ID: 16529927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.
    Caldwell GW
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):30-41. PubMed ID: 19649835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
    Crosignani S; Page P; Missotten M; Colovray V; Cleva C; Arrighi JF; Atherall J; Macritchie J; Martin T; Humbert Y; Gaudet M; Pupowicz D; Maio M; Pittet PA; Golzio L; Giachetti C; Rocha C; Bernardinelli G; Filinchuk Y; Scheer A; Schwarz MK; Chollet A
    J Med Chem; 2008 Apr; 51(7):2227-43. PubMed ID: 18318469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chemical approach to the pharmaceutical optimization of an anti-HIV protein.
    Miranda LP; Shao H; Williams J; Chen SY; Kong T; Garcia R; Chinn Y; Fraud N; O'Dwyer B; Ye J; Wilken J; Low DE; Cagle EN; Carnevali M; Lee A; Song D; Kung A; Bradburne JA; Paliard X; Kochendoerfer GG
    J Am Chem Soc; 2007 Oct; 129(43):13153-9. PubMed ID: 17915868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to the design of HIV protease inhibitors with improved resistance profiles.
    Gulnik SV; Eissenstat M
    Curr Opin HIV AIDS; 2008 Nov; 3(6):633-41. PubMed ID: 19373035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.
    Gaillard P; Jeanclaude-Etter I; Ardissone V; Arkinstall S; Cambet Y; Camps M; Chabert C; Church D; Cirillo R; Gretener D; Halazy S; Nichols A; Szyndralewiez C; Vitte PA; Gotteland JP
    J Med Chem; 2005 Jul; 48(14):4596-607. PubMed ID: 15999997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.
    Pisani L; Muncipinto G; Miscioscia TF; Nicolotti O; Leonetti F; Catto M; Caccia C; Salvati P; Soto-Otero R; Mendez-Alvarez E; Passeleu C; Carotti A
    J Med Chem; 2009 Nov; 52(21):6685-706. PubMed ID: 19810674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspects of successful drug discovery and development.
    Pauwels R
    Antiviral Res; 2006 Sep; 71(2-3):77-89. PubMed ID: 16828174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling.
    Székely R; Wáczek F; Szabadkai I; Németh G; Hegymegi-Barakonyi B; Eros D; Szokol B; Pató J; Hafenbradl D; Satchell J; Saint-Joanis B; Cole ST; Orfi L; Klebl BM; Kéri G
    Immunol Lett; 2008 Mar; 116(2):225-31. PubMed ID: 18258308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective optimization of side activities: the SOSA approach.
    Wermuth CG
    Drug Discov Today; 2006 Feb; 11(3-4):160-4. PubMed ID: 16533714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.